Acute complications

Scott Howard, Raul C. Ribeiro, Ching Hon Pui

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Citations (Scopus)

Abstract

Introduction The most common cause of early treatment failure among patients with childhood leukemia is death due to acute complications of the leukemia itself or its initial treatment. Despite the increasing intensity of treatment for acute lymphoblastic leukemia (ALL) in children, improvements in supportive care have reduced the rate of death due to acute complications from 10% in the early 1970s to less than 2% in the 1990s, and these improvements have had an important impact on event-free survival estimates for these patients. In fact, studies of the Medical Research Council (MRC) found that the rate of treatment-related death among children with ALL decreased from 9% in the 1980s (UKALL VIII trial) to 2% in the 1990s (UKALL X and XI trials). Hence, the 6% improvement in the 5-year event-free survival estimate during the same period (from 55% to 61%) can be attributed largely to advances in supportive care. The rate of toxic death associated with therapy for acute myeloid leukemia (AML) and relapsed ALL has also decreased over time but remains unacceptably high at 10% or greater in many studies. In countries with limited resources, death from toxicity accounts for more cases of treatment failure than does relapse in both AML and ALL. Acute complications include “early” complications (those occurring within the first 2 weeks of therapy) and “on-therapy” complications (those occurring after the first 2 weeks of therapy). “Late” complications are those occurring after recovery from the final dose of chemotherapy (Table 29.1).

Original languageEnglish (US)
Title of host publicationChildhood Leukemias, Second Edition
PublisherCambridge University Press
Pages709-749
Number of pages41
ISBN (Electronic)9780511471001
ISBN (Print)0521825199, 9780521825191
DOIs
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment Failure
Acute Myeloid Leukemia
Therapeutics
Disease-Free Survival
Leukemia
Mortality
Poisons
Biomedical Research
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Howard, S., Ribeiro, R. C., & Pui, C. H. (2006). Acute complications. In Childhood Leukemias, Second Edition (pp. 709-749). Cambridge University Press. https://doi.org/10.1017/CBO9780511471001.030

Acute complications. / Howard, Scott; Ribeiro, Raul C.; Pui, Ching Hon.

Childhood Leukemias, Second Edition. Cambridge University Press, 2006. p. 709-749.

Research output: Chapter in Book/Report/Conference proceedingChapter

Howard, S, Ribeiro, RC & Pui, CH 2006, Acute complications. in Childhood Leukemias, Second Edition. Cambridge University Press, pp. 709-749. https://doi.org/10.1017/CBO9780511471001.030
Howard S, Ribeiro RC, Pui CH. Acute complications. In Childhood Leukemias, Second Edition. Cambridge University Press. 2006. p. 709-749 https://doi.org/10.1017/CBO9780511471001.030
Howard, Scott ; Ribeiro, Raul C. ; Pui, Ching Hon. / Acute complications. Childhood Leukemias, Second Edition. Cambridge University Press, 2006. pp. 709-749
@inbook{01a4e8d5cd174fcc97015fa0041f9a95,
title = "Acute complications",
abstract = "Introduction The most common cause of early treatment failure among patients with childhood leukemia is death due to acute complications of the leukemia itself or its initial treatment. Despite the increasing intensity of treatment for acute lymphoblastic leukemia (ALL) in children, improvements in supportive care have reduced the rate of death due to acute complications from 10{\%} in the early 1970s to less than 2{\%} in the 1990s, and these improvements have had an important impact on event-free survival estimates for these patients. In fact, studies of the Medical Research Council (MRC) found that the rate of treatment-related death among children with ALL decreased from 9{\%} in the 1980s (UKALL VIII trial) to 2{\%} in the 1990s (UKALL X and XI trials). Hence, the 6{\%} improvement in the 5-year event-free survival estimate during the same period (from 55{\%} to 61{\%}) can be attributed largely to advances in supportive care. The rate of toxic death associated with therapy for acute myeloid leukemia (AML) and relapsed ALL has also decreased over time but remains unacceptably high at 10{\%} or greater in many studies. In countries with limited resources, death from toxicity accounts for more cases of treatment failure than does relapse in both AML and ALL. Acute complications include “early” complications (those occurring within the first 2 weeks of therapy) and “on-therapy” complications (those occurring after the first 2 weeks of therapy). “Late” complications are those occurring after recovery from the final dose of chemotherapy (Table 29.1).",
author = "Scott Howard and Ribeiro, {Raul C.} and Pui, {Ching Hon}",
year = "2006",
month = "1",
day = "1",
doi = "10.1017/CBO9780511471001.030",
language = "English (US)",
isbn = "0521825199",
pages = "709--749",
booktitle = "Childhood Leukemias, Second Edition",
publisher = "Cambridge University Press",
address = "United Kingdom",

}

TY - CHAP

T1 - Acute complications

AU - Howard, Scott

AU - Ribeiro, Raul C.

AU - Pui, Ching Hon

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Introduction The most common cause of early treatment failure among patients with childhood leukemia is death due to acute complications of the leukemia itself or its initial treatment. Despite the increasing intensity of treatment for acute lymphoblastic leukemia (ALL) in children, improvements in supportive care have reduced the rate of death due to acute complications from 10% in the early 1970s to less than 2% in the 1990s, and these improvements have had an important impact on event-free survival estimates for these patients. In fact, studies of the Medical Research Council (MRC) found that the rate of treatment-related death among children with ALL decreased from 9% in the 1980s (UKALL VIII trial) to 2% in the 1990s (UKALL X and XI trials). Hence, the 6% improvement in the 5-year event-free survival estimate during the same period (from 55% to 61%) can be attributed largely to advances in supportive care. The rate of toxic death associated with therapy for acute myeloid leukemia (AML) and relapsed ALL has also decreased over time but remains unacceptably high at 10% or greater in many studies. In countries with limited resources, death from toxicity accounts for more cases of treatment failure than does relapse in both AML and ALL. Acute complications include “early” complications (those occurring within the first 2 weeks of therapy) and “on-therapy” complications (those occurring after the first 2 weeks of therapy). “Late” complications are those occurring after recovery from the final dose of chemotherapy (Table 29.1).

AB - Introduction The most common cause of early treatment failure among patients with childhood leukemia is death due to acute complications of the leukemia itself or its initial treatment. Despite the increasing intensity of treatment for acute lymphoblastic leukemia (ALL) in children, improvements in supportive care have reduced the rate of death due to acute complications from 10% in the early 1970s to less than 2% in the 1990s, and these improvements have had an important impact on event-free survival estimates for these patients. In fact, studies of the Medical Research Council (MRC) found that the rate of treatment-related death among children with ALL decreased from 9% in the 1980s (UKALL VIII trial) to 2% in the 1990s (UKALL X and XI trials). Hence, the 6% improvement in the 5-year event-free survival estimate during the same period (from 55% to 61%) can be attributed largely to advances in supportive care. The rate of toxic death associated with therapy for acute myeloid leukemia (AML) and relapsed ALL has also decreased over time but remains unacceptably high at 10% or greater in many studies. In countries with limited resources, death from toxicity accounts for more cases of treatment failure than does relapse in both AML and ALL. Acute complications include “early” complications (those occurring within the first 2 weeks of therapy) and “on-therapy” complications (those occurring after the first 2 weeks of therapy). “Late” complications are those occurring after recovery from the final dose of chemotherapy (Table 29.1).

UR - http://www.scopus.com/inward/record.url?scp=79955882617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955882617&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511471001.030

DO - 10.1017/CBO9780511471001.030

M3 - Chapter

SN - 0521825199

SN - 9780521825191

SP - 709

EP - 749

BT - Childhood Leukemias, Second Edition

PB - Cambridge University Press

ER -